Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Bullboard Posts
Post by AndrewKenon Jan 30, 2017 1:56pm
96 Views
Post# 25773395

TODAY! Year End 2016 Financial Results - Lattice Biologics

TODAY! Year End 2016 Financial Results - Lattice Biologics

Financial results to be released after market on Monday, January 30, 2017

SCOTTSDALE, AZ--(Marketwired - January 27, 2017) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) (the "Company") announced today that it will release its year ended September 30, 2016 financial results after market on Monday, January 30, 2017. Following this, Guy Cook, Chief Executive Officer, and Cheryl Farmer, Chief Financial Officer, will host a conference call at 6:30 a.m. PDT on Tuesday, January 31, 2017 to review the results. A question and answer session will follow the corporate update.

     
CONFERENCE CALL DETAILS:    
DATE:   Tuesday, January 31, 2017
TIME:   6:30 AM Pacific Time
DIAL-IN NUMBER:   (213) 416-1560
ATTENDEE PIN:   286 6963#
     

Register for the online webinar for full meeting functionality:
https://www.anymeeting.com/PIID=EC59DE8987493B

A recording of the call will be archived on the Company's website at:
https://www.latticebiologics.com/webinars/

Lattice Biologics Ltd.

Guy Cook,
Chief Executive Officer
Telephone No: (480) 563-0800

About Lattice Biologics Ltd.:
Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.

Bullboard Posts